Online citations, reference lists, and bibliographies.
← Back to Search

Recent Advances In The Diagnosis Of Malignant Mesothelioma: Focus On Approach In Challenging Cases And In Limited Tissue And Cytologic Samples

S. Monaco, M. Mehrad, S. Dacic
Published 2018 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Mesothelial proliferations can be diagnostically challenging in small specimens, such as body fluid cytology and small tissue biopsies. A great morphologic challenge for pathologists is the separation of benign reactive mesothelial proliferations from malignant mesotheliomas. Reactive mesothelial proliferations may have histologic features that resemble malignancy including increased cellularity, cytologic atypia, and mitoses. Recent advances in mesothelioma genetics resulted in identification of BAP1 mutations and p16 deletions as features of malignant mesotheliomas. Hence, BAP1 immunohistochemistry and fluorescence in situ hybridization for p16 emerged as 2 most common diagnostically helpful ancillary studies used on limited samples when the question is whether the proliferation is malignant or benign. In contrast, separation of mesothelioma from other malignancies is relatively straight forward using morphology and immunohistochemical stains. The choice of antibody panel to be applied in an individual case is driven by morphology, either epithelioid or sarcomatoid. This brief review will focus on morphology and ancillary testing of mainly pleural mesothelial proliferations.
This paper references
10.1097/JTO.0b013e318211127a
Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid Mesothelioma
Kyuichi Kadota (2011)
10.1038/modpathol.3800775
SYT-SSX fusion is absent in sarcomatoid mesothelioma allowing its distinction from synovial sarcoma of the pleura
N. Weinbreck (2007)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
10.1002/dc.21398
Diagnostic usefulness of EMA, IMP3, and GLUT‐1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations
K. Ikeda (2011)
10.1038/modpathol.2009.180
Sarcomatoid mesothelioma: a clinical–pathologic correlation of 326 cases
S. Klebe (2010)
10.1097/PAS.0000000000000394
BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations
B. Sheffield (2015)
Mesothelial tumors-diffuse malignant mesothelioma
F Galateau-Salle (2015)
10.1111/cas.12769
Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue
T. Hida (2015)
10.1111/cyt.12250
Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed‐Type Malignant Mesothelioma: a secondary publication
A. Hjerpe (2015)
10.1043/2010-0086-RAR.1
Sarcomatoid neoplasms of the lung and pleura.
W. Travis (2010)
10.1093/CARCIN/23.7.1127
Alterations of the p16(INK4) locus in human malignant mesothelial tumors.
T. Hirao (2002)
10.1038/modpathol.2011.146
A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma
Kyuichi Kadota (2012)
10.5858/arpa.2012-0108-OA
p16 Deletion in sarcomatoid tumors of the lung and pleura.
N. Tochigi (2013)
10.1378/chest.09-1951
Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
S. Savic (2010)
10.1016/j.humpath.2015.06.024
BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
Stephanie M. McGregor (2015)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1038/modpathol.2008.45
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
S. Chiosea (2008)
10.1111/j.1349-7006.2012.02223.x
Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma
Yoshie Yoshikawa (2012)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
10.1002/cncy.21269
Morphology of 9p21 homozygous deletion‐positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology
S. Matsumoto (2013)
10.1309/AJCPP5R2ZJZKCLWN
The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
S. Monaco (2011)
10.1002/cncy.21342
The diagnosis of malignant mesothelioma in effusion cytology
A. Paintal (2013)
10.1111/cge.12501
A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma
K.A.W. Wadt (2015)
10.1016/S0140-6736(03)13079-6
Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial
N. Maskell (2003)
10.1097/JTO.0000000000000663
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.
W. Travis (2015)
10.5858/arpa.2012-0112-ra
The Separation of Benign and Malignant Mesothelial Proliferations
A. Churg (2012)
10.1002/dc.23491
BAP1 Immunostain and CDKN2A (p16) FISH Analysis
A. Walts (2016)
The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura.
L. Chirieac (2011)
10.1038/modpathol.2009.186
CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival
A. Krasinskas (2010)
10.1097/JTO.0b013e31829e7ef9
Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations
M. Zauderer (2013)
10.4103/1742-6413.99170
Parakeratotic-like cells in effusions — A clue to diagnosis of malignant mesothelioma
L. Gao (2012)
10.1038/modpathol.2012.58
A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma
Kyuichi Kadota (2012)
10.1159/000443483
CT Scan-Guided Abrams' Needle Pleural Biopsy versus Ultrasound-Assisted Cutting Needle Pleural Biopsy for Diagnosis in Patients with Pleural Effusion: A Randomized, Controlled Trial
M. Metintas (2016)
10.5858/arpa.2015-0240-SA
New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
A. Churg (2016)
10.5858/arpa.2012-0214-OA
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
A. Husain (2013)
10.1097/JTO.0b013e31820ce2c7
Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma
S. Kao (2011)
10.1158/0008-5472.CAN-05-3907
Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.
Fernando López-Ríos (2006)
10.1002/dc.23501
Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations
K. Nabeshima (2016)
Fine needle aspiration cytology of malignant mesothelioma.
G. Sterrett (1987)
10.1038/modpathol.2008.125
Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review
S. Klebe (2008)
10.1309/AJCPT94JVWIHBKRD
Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
D. Wu (2013)
10.1097/PAS.0000000000000529
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens
H. Hwang (2016)
10.1158/0008-5472.CAN-14-1008
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
10.1097/PAS.0b013e318218985b
Oncofetal Protein IMP3, a New Diagnostic Biomarker to Distinguish Malignant Mesothelioma From Reactive Mesothelial Proliferation
M. Shi (2011)
10.1038/modpathol.2012.39
Pleomorphic mesothelioma: report of 10 cases
N. Ordóñez (2012)
10.1046/j.1365-2559.2003.01686.x
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2
R. Attanoos (2003)



This paper is referenced by
10.1097/MCP.0000000000000489
Updates in the diagnosis and treatment of malignant pleural mesothelioma
D. Katzman (2018)
10.1002/cncy.22326
Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology
Martin Chevrier (2020)
10.1177/1753466618808660
Biomarkers in the diagnosis of pleural diseases: a 2018 update
J. M. Porcel (2018)
10.3390/cancers10060203
Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on
C. Ledda (2018)
10.1007/s00428-021-03031-7
Pleural mesothelioma classification update
Mary Beth Beasley (2021)
10.1002/rcr2.664
A challenging diagnosis of malignant mesothelioma with osteosarcomatous differentiation metastasizing to bone
M. Brown (2020)
10.6092/1828-6550/APMB.106.1.2018.SD2
Pleural diffuse mesothelial lesions: A challenge for pathologists
A. Ieni (2018)
10.21037/JXYM-20-79
Biomarkers in the diagnosis and treatment of malignant pleural disease: an integrative review
F. Buttitta (2020)
10.1002/cncy.22368
The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas.
Livia Bernardi (2020)
10.1016/j.lungcan.2020.10.020
Homozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre.
K. Marshall (2020)
10.1177/0003702820924726
Differentiating Between Malignant Mesothelioma and Other Pleural Lesions Using Fourier Transform Infrared Spectroscopy
Fatlinda Sadiku-Zehri (2020)
10.1016/j.jtho.2019.06.020
Pathologic considerations and standardization in mesothelioma clinical trials.
M. Tsao (2019)
10.1183/2312508x.10023619
Optimal diagnosis and treatment of malignant pleual disease: challenging the guidelines
D. Arnold (2020)
Semantic Scholar Logo Some data provided by SemanticScholar